The artificial pericardium prosthesis “PeriBeam®” will be exhibited at “The 56th Annual Meeting of the Japanese Society for Cardiovascular Surgery” (Saturday, February 21st to Monday, February 23rd, 2026). (JMS booth)
With Aichi Children’s Health and Medical Center, TamaBio launches Clinical Observational Study Using “PeriBeam®” Pericardial Membrane.
PeriBeam®, the FDA listed Pericardial Membrane, manufactured by TamaBio, a FDA registered establishment, was exported to the United States for the first time this week.
At TERMIS-AP 2025, the possibility of our technology being used to treat myocardial infarction was mentioned.
The artificial dura mater “DuraBeam®” will be exhibited at the 84th Annual Meeting of the Japan Neurosurgical Society (Wednesday, October 29th, 2025 – Saturday, November 1st, 2025).
We will be exhibiting the artificial pericardium prosthesis “PeriBeam®” at The 78th Annual Scientific Meeting of the Japanese Association for Thoracic Surgery (2025) (Thursday, October 23rd to Saturday, October 25th, 2025).
TamaBio will be sponsoring the 36th Japanese Society of Diencephalo-Pituitary Tumors (Thursday, March 5th and Friday, March 6th, 2026, Fukuoka City, Japan).
TamaBio has received a notice of grant decision for subsidy to support the international patent application for our domestic joint patent inventions with Tohoku University [Regenerative Medical Devices – Brain Tissue etc. Damage Repair Sheet].
TamaBio will be sponsoring the 57th Spine Surgery Club Meeting to be held on Aug.23rd at Nagasaki.
Nippon Medical School and TamaBio Sign New Joint Research Agreement : Regenerative Therapy for Infarcted Myocardium Using Epicardial Approach
